Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Harvard Business School
McKinsey
Boehringer Ingelheim
Dow

Last Updated: August 11, 2022

Investigational Drug Information for Ruzasvir


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Ruzasvir?

Ruzasvir is an investigational drug.

There have been 8 clinical trials for Ruzasvir. The most recent clinical trial was a Phase 2 trial, which was initiated on December 10th 2015.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Merck Sharp & Dohme Corp. and [disabled in preview].

There are two US patents protecting this investigational drug and thirty-three international patents.

Recent Clinical Trials for Ruzasvir
TitleSponsorPhase
Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)Merck Sharp & Dohme Corp.Phase 2
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)Merck Sharp & Dohme Corp.Phase 2
A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)Merck Sharp & Dohme Corp.Phase 1

See all Ruzasvir clinical trials

Clinical Trial Summary for Ruzasvir

Top disease conditions for Ruzasvir
Top clinical trial sponsors for Ruzasvir

See all Ruzasvir clinical trials

US Patents for Ruzasvir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ruzasvir See Plans and Pricing Process for preparing substituted tetracyclic heterocycle compounds Merck Sharp & Dohme Corp. (Rahway, NJ) See Plans and Pricing
Ruzasvir See Plans and Pricing Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases Merck Sharp & Dohme Corp. (Rahway, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ruzasvir

Drugname Country Document Number Estimated Expiration Related US Patent
Ruzasvir World Intellectual Property Organization (WIPO) WO2016196932 2035-06-04 See Plans and Pricing
Ruzasvir Argentina AR094496 2033-01-16 See Plans and Pricing
Ruzasvir Australia AU2013374112 2033-01-16 See Plans and Pricing
Ruzasvir Canada CA2898049 2033-01-16 See Plans and Pricing
Ruzasvir Chile CL2015001971 2033-01-16 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Harvard Business School
McKinsey
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.